natgillin/translations-raw huggingface dataset:
Use according to claim 4, wherein the formulation comprises benzyl alcohol, phenol and/or m-cresol. 
Uporaba sukladno zahtjevu 4, pri čemu formulacija sadrži benzil alkohol, fenol i/ili m-kresol.
Method for limiting the tendency of FSH to dissociate in a liquid FSH formulation wherein the method comprises the step of an addition of salts comprising pharmaceutically acceptable alkali metal cations to said formulation, wherein said salt is Na2S04 or a combination of NaCl and Na2S04. 
Postupak limitiranja tendencije disociranja FSH u tekuću FSH formulaciju pri čemu postupak sadrži korak dodavanja soli koje sadrže farmaceutski prihvatljive katione alkalijskih metala u navedenu formulaciju, pri čemu je navedena sol Na2S04 ili kombinaciju NaCl i Na2S04.
Method according to claim 7, wherein the FSH is rFSH. 
Postupak sukladno zahtjevu 7, pri čemu je FSH, rFSH.
Method according to claim 14 wherein the preservative is selected from the group consisting of benzyl alcohol, phenol and m-cresol. 
Postupak sukladno zahtjevu 9, pri čemu je konzervans odabran iz skupine koja se sastoji od benzil alkohola, fenola i m-kresola.
at least one dividing unit comprising dividing means, and 
barem jednu jedinicu za dijeljenje koja sadrži sredstva za dijeljenje, i
The installation according to claim 1, wherein the at least one dividing unit comprises moving beads as dividing means made of a material selected from the group comprising quartz sand, glass, porcelain, zirconium oxide, zirconium silicate and mixtures thereof, optionally comprising minor quantities of further minerals. 
Instalacija prema bilo kojem od prethodnih zahtjeva, naznačena time da barem jedna jedinica za dijeljenje sadrži kao sredstva za dijeljenje pokretne kuglice izrađene od materijala koji je odabran iz skupine koja sadrži kvarcni pijesak, staklo, porculan, cirkonijev oksid, cirkonijev silikat i njihove smjese, te proizvoljno sadrži male količine drugih minerala.
The installation according to claim 10, wherein the at least one membrane filtration unit is a cross flow membrane filtration device comprising at least one tube filter membrane having an inner diameter of the tube from 0.01 mm to 25 mm, or from 0.1 mm to 10 mm. 
Instalacija prema zahtjevu 10, naznačena time da filtracijski uređaj s membranom s unakrsnim strujanjem sadrži barem jednu cjevastu filtarsku membranu koja ima unutrašnji promjer cijevi od 0.01 mm do 25 mm, poželjno od 0.1 mm do 10 mm.
The installation according to claim 12, wherein the membrane is made from a sintered material, a porous porcelain, a synthetic polymer, polyethylene, polypropylene, Teflon®, or any mixture thereof. 
Instalacija prema zahtjevu 12, naznačena time da je materijal membrane odabran iz skupine koju čine sinterirani materijal, porozni porculan, sintetski polimeri kao što su polietilen, polipropilen ili Teflon®, te njihove smjese.
A method of conjugating a saccharide to a protein carrier using carbodiimide condensation chemistry, wherein the saccharide comprises (for instance as part of its repeating unit), or has been derivatised to comprise, amino and/or carboxyl groups, and wherein the protein carrier comprises, or has been derivatised to comprise, amino and/or carboxyl groups, comprising the steps of: 
Postupak konjugiranja saharida s proteinskin nosačem karbodiimidnim kondenziranjem, gdje saharid sadrži (primjerice kao dio svoje repetitivne jedinice), ili je tako deriviran da sadrži, amino i/ili karboksilne skupine, te gdje proteinski nosač sadrži, ili je tako deriviran da sadrži, amino i/ili karboksilne skupine, naznačen time što se sastoji u koracima:
III) if the saccharide comprises both amino and carboxyl groups and the protein carrier comprises both amino and carboxyl groups: 
III) – ako saharid sadrži i amino i karboksilne skupine i proteinski nosač sadrži i amino i karboksilne skupine:
The method of claims 1-3, wherein the saccharide and/or protein carrier has been derivatised to comprise amino or carboxyl groups. 
Postupak u skladu s patentnim zahtjevima 1-3, naznačen time što je saharid i/ili proteinski nosač tako deriviran da sadrži amino ili karboksilne skupine.
C2-6 alkenyloxy, or a pharmaceutically acceptable salt thereof, or a solvate thereof. 
C2-6 alkeniloksi, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
Use of the compound as claimed in any one of claims 1 to 20 or a pharmaceutically acceptable salt thereof, or a solvate thereof in the manufacture of a medicament for treating or preventing a disease selected from the group consisting of organ transplant rejection, graft versus host reaction after transplantation, autoimmune disease, allergic diseases and chronic myeloproliferative disease. 
Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegove farmaceutski prihvatljive soli ili njegovog solvata, naznačena time što je spoj namijenjen proizvodnji medikamenta za liječenje ili sprječavanje bolesti koju se bira iz skupine koju čine odbacivanje presađenog organa, reakcija presatka prema domaćinu nakon presađivanja, autoimuna bolest, alergijske bolesti i kronična mijeloproliferativna bolest.
The pharmaceutical composition according to claim 7 or 8 additionally comprising an inert filler and/or solvent. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 7 ili farmaceutski pripravak u skladu s patentnim zahtjevom 8, naznačen time što dodatno sadrži inertno punilo i/ili otapalo.
A medicament in the form of tablets, capsules or injections for the treatment of cancerous diseases comprising a compound according to any of claims 1 to 5 or a pharmaceutical composition according to any of claims 7 to 9. The medicament according to claim 11 intended for prostate cancer treatment. 
Medikament u obliku tableta, kapsula ili injekcije, namijenjen liječenju kanceroznih bolesti, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 5 ili farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 7 do 9.
A method for non-therapeutically enhancing the performance of a mammal, said enhanced performance manifested as reduced oxygen consumption (VO2) during physical exercise, characterized in that inorganic nitrate, nitrite or a combination thereof is administered perorally, wherein the nitrate dose is 0.01 - 10 mmol sodium nitrate/kg bodyweight/day, the nitrite dose is 0.001-1 mmol/kg bodyweight/day, and wherein the dose ratio interval when nitrate and nitrite are administered in combination is 5:1 to 100:1 (nitrate:nitrite), wherein said performance is enhanced as compared with the physical performance of said mammal during said physical exercise in the absence of said administration of inorganic nitrate and/or nitrite. 
Metoda za neterapijsko poboljšavanje izvedbe kod sisavaca, navedeno poboljšanje izvedbe prikazuje se kao smanjena potrošnja kisika (VO2) za vrijeme tjelesne aktivnosti, karakterizirana na način da se peroralno daju anorganski nitrat, nitrit ili njihova kombinacija, pri čemu je doza nitrata 0.01 – 10 mmol natijevog nitrata/kg tjelesne težine/dan, doza nitrita je 0.001 – 1 mmol/kg tjelesne težine/dan, i pri čemu je interval omjera doze kada se nitrat i nitrit daju u kombinaciji od 5:1 do 100:1 (nitrat:nitrit), pri čemu je navedena izvedba poboljšana u usporedbi s tjelesnom izvedbom navedenog sisavca za vrijeme navedene tjelesne aktivnosti u odsutnosti navedenog davanja anorganskog nitrata i/ili nitrita.
The use of inorganic nitrate or nitrite or a combination thereof for non-therapeutically enhancing the performance of a mammal, said enhanced performance manifested as reduced oxygen consumption (VO2) during physical exercise, characterized in that inorganic nitrate, nitrite or a combination thereof is administered perorally, wherein the nitrate dose is 0.01 - 10 mmol sodium nitrate/kg bodyweight/day, the nitrite dose is 0.001-1 mmol/kg bodyweight/day, and wherein the dose ratio interval when nitrate and nitrite are administered in combination is 5:1 to 100:1 (nitrate:nitrite), wherein said performance is enhanced as compared with the physical performance of said mammal during said physical exercise in the absence of said administration of inorganic nitrate and/or nitrite. 
Uporaba anorganskog nitrata ili nitrita ili njihove kombinacije za neterapijsko poboljšavanje izvedbe u sisavaca, navedeno poboljšanje izvedbe prikazuje se kao smanjena potrošnja kisika (VO2) za vrijeme tjelesne aktivnosti, karakterizirana na način da se peroralno daju anorganski nitrat, nitrit ili njihova kombinacija, pri čemu je doza nitrata 0.01 – 10 mmol natijevog nitrata/kg tjelesne težine/dan, doza nitrita je 0.001 – 1 mmol/kg tjelesne težine/dan, i pri čemu je interval omjera doze kada se nitrat i nitrit daju u kombinaciji od 5:1 do 100:1 (nitrat:nitrit), pri čemu je navedena izvedba poboljšana u usporedbi s tjelesnom izvedbom navedenog sisavca za vrijeme navedene tjelesne aktivnosti u odsutnosti navedenog davanja anorganskog nitrata i/ili nitrita.
Rf and Rg are each, independently, H, or C1-C6 alkyl that is optionally substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy, keto, amino, C1-C6 alkylamino, di(C1-C6alkyl)amino, trifluoromethyl, aryl, heteroaryl or hydroxyl; or Rf and Rg, together with the nitrogen atom to which they are attached, form a heterocycle comprising 1 or 2, 5- or 6-member rings and optionally 1-3 additional heteroatoms selected from N, o and S; 
svaki od Rf i Rg je, neovisno, H, ili C1-C6 alkil, koji može biti supstituiran s halogenom, C1-C6 alkilom, C1-C6 alkoksi, keto, amino, C1-C6 alkilamino, di(C1-C6 alkil)amino, trifluormetilom, arilom, heteroarilom ili hidroksilom; ili Rf i Rg, zajedno s atomom dušika na kojeg su vezani, tvore heterocikl, koji se sastoji od 1 ili 2 5- ili 6-eročlana prstena i izborno 1-3 dodatna heteroatoma, koje se bira između N, O i S;
The compound of claim 1, wherein the compound is of formula II or a pharmaceutically acceptable salt thereof, wherein R7 is selected from the group consisting of: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je spoj formule II [image], ili njegova farmaceutski prihvatljiva sol, gdje se bira iz skupine koju čine:
Rh and Ri are each, independently, H, or C1-C6 alkyl that is optionally substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy, keto, amino, C1-C6 alkylamino, di(C1-C6 alkyl)amino, trifluoromethyl, aryl, heteroaryl or hydroxyl; or Rh and Ri, together with the nitrogen atom to which they are attached, form a heterocycle comprising 1 or 2, 5- or 6-member rings and optionally 1-3 additional heteroatoms selected from N, o and S; 
svaki od Rh i Ri je, neovisno, H, ili C1-C6 alkil, koji može biti supstituiran s halogenom, C1-C6 alkilom, C1-C6 alkoksi, keto, amino, C1-C6 alkilamino, di(C1-C6 alkil)amino, trifluormetilom, arilom, heteroarilom ili hidroksilom; ili Rh i Ri, zajedno s atomom dušika na kojeg su vezani, tvore heterocikl, koji se sastoji od 1 ili 2 5- ili 6-eročlana prstena i izborno 1-3 dodatna heteroatoma, koje se bira između N, O i S;
The compound of claim 1 wherein the compound is of the formula III: or a salt thereof, 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je spoj formule III: [image], ili njegova sol, gdje
An isolated antibody or fragment thereof that recognizes a conformational epitope of a HER3 receptor, wherein the conformational epitope comprises amino acid residues 265-277, 315 within domain 2 and amino acid residues 571, 582-584, 596-597, 600-602, 609-615 within domain 4 of the HER3 receptor of SEQ ID NO: 1, and wherein the antibody or fragment thereof blocks both ligand-dependent and ligand-independent signal transduction of HER3. 
Izolirano protutijelo ili njegov fragment koji prepoznaje konformacijski epitop za HER3-receptor, naznačen/o time, da konformacijski epitop obuhvaća aminokiselinske ostatke 265-277, 315 unutar domene 2 i aminokiselinske ostatke 571, 582-584, 596-597, 600-602, 609-615 unutar domene 4 od HER3-receptora od SEQ ID NO:1, te pritom protutijelo ili njegov fragment blokira obje signalne transdukcije od HER3, onu koja je ovisna o ligandu i onu koja nije ovisna o ligandu.
binds to the inactive state of the HER3 receptor; or 
se veže na neaktivno stanje od HER3-receptora; ili
to activate signal transduction. 
aktivirati signalnu transdukciju.
The isolated antibody or fragment thereof of claim 1, wherein the isolated antibody or fragment thereof recognizes a conformational epitope of a first HER3 receptor, wherein: 
Izolirano protutijelo ili njegov fragment prema zahtjevu 1, naznačen/o time, da izolirano protutijelo ili njegov fragment prepoznaje konformacijski epitop od prvog HER3-receptora, te pritom:
binding of the antibody or fragment thereof to the HER3 receptor in the absence of a HER3 ligand reduces ligand-independent formation of a HER2-HER3 protein complex in a cell which expresses HER2 and HER3; or 
vezanje protutijela ili njegovog fragmenta na HER3-receptor u odsutnosti HER3-liganda, smanjuje tvorbu neovisnu o ligandu, proteinskog kompleksa HER2-HER3, u stanici koja izražava HER2 i HER3; ili
binding of the antibody or fragment thereof to the HER3 receptor in the presence of a HER3 ligand reduces ligand-dependent formation of a HER2-HER3 protein complex in a cell which expresses HER2 and HER3. 
vezanje protutijela ili njegovog fragmenta na HER3-receptor u prisutnosti HER3-liganda, smanjuje tvorbu ovisnu o ligandu, proteinskog kompleksa HER2-HER3, u stanici koja izražava HER2 i HER3.
A pharmaceutical composition comprising an antibody or fragment thereof selected from any one of the previous claims and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća protutijelo ili njegov fragment odabran prema bilo kojem od prethodnih zahtjeva, i farmaceutski prihvatljiv nosač.
The pharmaceutical composition of claim 30, wherein: 
Farmaceutski sastav prema zahtjevu 30, naznačen time, da:
when the additional therapeutic agent is an mTOR inhibitor, the mTOR inhibitor is selected from the group consisting of Temsirolimus/Torisel®, ridaforolimus / Deforolimus, AP23573, MK8669, everolimus /Affinitor®; 
kada je dodatno terapeutsko sredstvo jedan mTOR-inhibitor, tada se mTOR-inhibitor odabire iz skupine koju čine: Temsirolimus/Torisel®, ridaforolimus/Deforolimus, AP23573, MK8669, everolimus/Affinitor®;
The antibody or fragment thereof according to any one of claims 1 to 27 or the composition according to any one of claims 28 to 31 for use in treating a cancer according to claim 34, wherein the cancer is selected from the group consisting of breast cancer, colorectal cancer, lung cancer, multiple myeloma, ovarian cancer, liver cancer, gastric cancer, pancreatic cancer, prostate cancer, acute myeloid leukemia, chronic myeloid leukemia, osteosarcoma, squamous cell carcinoma, peripheral nerve sheath tumors, schwannoma, head and neck cancer, bladder cancer, esophageal cancer, glioblastoma, clear cell sarcoma of soft tissue, malignant mesothelioma, neurofibromatosis, renal cancer, and melanoma. 
Protutijelo ili njegov fragment prema bilo kojem od zahtjeva 1 do 27, ili sastav prema bilo kojem od zahtjeva 28 do 31, za uporabu u liječenju raka prema zahtjevu 33, naznačen/o time, da je rak odabran iz skupine koja se sastoji od sljedećih: rak dojke, kolorektalni rak, rak pluća, višestruki mijelom, rak jajnika, rak jetre, rak želudca, rak gušterače, rak prostate, akutna mijeloidna leukemija, kronična mijeloidna leukemija, osteosarkom, karcinom pločastih stanica, tumori perifernih obloženih živaca, švanom, rak glave i vrata, rak mjehura, rak jednjaka, glioblastom, sarkom mekog tkiva -„clear cell sarkom“, maligni mezoteliom, neurofibromatoza, rak bubrega i melanom.
Vaccine comprising at least two fragments of Proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein a first fragment of said at least two fragments comprises at least 9 consecutive amino acid residues of amino acid residues 153 to 165 of PCSK9 according to SEQ ID No. 9 and a second fragment of said at least two fragments comprises at least 9 consecutive amino acid residues of amino acid residues 209 to 222 of PCSK9 according to SEQ ID No. 9. 
Cjepivo, naznačeno time, da obuhvaća najmanje dva fragmenta proproteinske konvertaze subtilizin/keksin tipa 9 (PCSK9), pri čemu barem jedan od navedena najmanje dva fragmenta sadrže najmanje devet uzastopnih aminokiselinskih ostataka od aminokiselinskih ostataka 153 do 165 od PCSK9 u skladu sa SEQ ID NO:9, i gdje barem jedan od navedena najmanje dva fragmenta sadrži najmanje devet uzastopnih aminokiselinskih ostataka od aminokiselinskih ostataka 209 do 222 od PCSK9 u skladu sa SEQ ID NO:9.
A CXCR1 antagonist for use in a method for the treatment of a subject having a tumor, wherein the method further comprises administration of a chemotherapeutic agent. 
Antagonist CXCR1, namijenjen upotrebi u postupku liječenja subjekta koji ima tumor, naznačen time što se postupak dodatno sastoji u primjeni kemoterapijskog sredstva.
The CXCR1 antagonist for use of Claim 1, wherein said chemotherapeutic agent is an anti-mitotic agent. 
Antagonist CXCR1, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je navedeno kemoterapijsko sredstvo antimitotsko sredstvo.
The CXCR1 antagonist for use of claim 4, wherein said anti-mitotic agent is selected from the group consisting of: docetaxel, doxorubicin, Paclitaxel, fluorouracil, vincristine, vinblastine, nocodazole, colchicine, podophyllotoxin, steganacin and combretastatin. 
Antagonist CXCR1, namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što navedeno antimitotsko sredstvo se bira iz skupine koju čine: docetaksel, doksorubicin, paklitaksel, fluoruracil, vinkristin, vinblastin, nokodazol, kolhicin, podofilotoksin, steganacin i kombretastatin.
The CXCR1 antagonist for use of Claim 1, wherein said tumor comprises cancer stem cells selected from the group consisting of: prostate cancer stem cells, ovarian cancer stem cells, breast cancer stem cells, skin cancer stem cells, non-small cell lung cancer stem cells, small-cell lung cancer stem cells, and esophageal adenocarcinoma stem cells. 
Antagonist CXCR1, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što navedeni tumor sadrži matične stanice raka, koje se bira iz skupine koju čine: matične stanice raka prostate, matične stanice raka jajnika, matične stanice raka dojke, matične stanice raka kože, matične stanice raka velikih stanica pluća, matične stanice raka malih stanica pluća, te matične stanice adenokarcinoma jednjaka.
The CXCR1 antagonist for use of claim 9, wherein said breast cancer tumor comprises breast cancer stem cells. 
Antagonist CXCR1, namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što navedeni rak dojke sadrži matične stanice raka dojke.
A method of producing a polypeptide comprising: culturing the host cell of Claim 9 in culture medium under conditions wherein the nucleic acid sequence is expressed, thereby producing polypeptides comprising the light and heavy chain variable regions; and 
kultiviranje stanice-domaćina iz zahtjeva 9 u kultivacijskom mediju pod uvjetima pod kojima se eksprimira sekvenca nukleinske kiseline, čime se proizvode polipeptidi koji sadrže varijabilne regije lakog i teškog lanca; i sakupljanje polipeptida iz stanice-domaćina ili kultivacijskog medija.
The antibody, or antigen binding fragment thereof, of Claim 1 comprising an antibody fragment selected from the group consisting of Fab, Fab', Fab'-SH, Fv, scFv, F(ab')2, and a diabody. 
Antitijelo, ili njegov antigen-vežući fragment, iz zahtjeva 1, naznačen time, što se fragment antitijela bira iz grupe koja se sastoji od Fab, Fab’, Fab’-SH, Fv, scFv, F(ab’)2 i dijatela.
an expression vector comprising a nucleic acid sequence encoding the light chain of the antibody, or antigen binding fragment thereof, of claim 4; and 
ekspresijski vektor koji uključuje sekvencu nukleinske kiseline koja kodira laki lanac antitijela, ili njegovog antigen-vežućeg fragmenta, iz zahtjeva 4; i
an expression vector comprising a nucleic acid sequence encoding the heavy chain of the antibody, or antigen binding fragment thereof, of claim 4. 
ekspresijski vektor koji uključuje sekvencu nukleinske kiseline koja kodira teški lanac antitijela, ili njegovog antigen-vežućeg fragmenta, iz zahtjeva 4.
A method of facilitating communications in a communications environment comprising a sender (300), a receiver (310) and firmware (350) of a processor, wherein the sender and receiver are isolated memory spaces, and wherein both sender and receiver operate under control of the firmware within a single physical machine, the firmware having access to the isolated memory spaces of the sender and receiver, said method comprising: 
Metoda olakšavanja komunikacije u komunikacijskom okolišu koji obuhvaća pošiljatelja (300), primatelja (310) i firmware (350) procesora, pri čemu su pošiljatelj i primatelj izolirani memorijski prostori, i pri čemu pošiljatelj i primatelj djeluju pod kontrolom firmwarea unutar jedinstvenog stroja, firmware ima pristup izoliranim memorijskim prostorima pošiljatelja i primatelja, navedena metoda obuhvaća:
receiving by the firmware (350) from the sender (300) a data transfer request to send data to the receiver (310), the data transfer request comprising: 
primanje od strane firmware (350) od pošiljatelja (300) zahtjeva za prijenos podataka primatelju (310), zahtjev za prijenos podataka obuhvaća:
pointers to memory buffers to be sent in the sender's isolated memory space; and a pre-authorization operation block (QAOB), the pre-authorization operation block (QAOB) indicating pre-authorisation to the firmware that the firmware may perform a data transfer asynchronously; 
pokazivače na memorijske ublaživače koji će biti poslani u izolirani memorijski prostor pošiljatelja; i predautorizacijski komunikacijski blok (QAOB), predautorizacijski operacijski blok (QAOB) koji ukazuje na predautorizaciju firmwarea da firmware može izvesti asinkroni prijenos podataka;
responsive to the receiver being able to receive the data, transferring (508) the data synchronously (508); 
odgovaranje na sposobnost primatelja za primanje podataka, sinkroni prijenos (508) podataka (508);
receiving another request from the sender, the another request to be sent to another receiver synchronously prior to completion of sending the request to the receiver asynchronously; 
primanje drugog zahtjeva od pošiljatelja, drugi zahtjev će biti poslan drugom primatelju sinkrono prije nego što je završen postupak slanja asinkronog zahtjeva;
the firmware determining (514) whether the receiver has an empty buffer to able to now receive the data; and 
određivanje firmwarea (514) ima li primatelj prazan ublaživač radi primanja podataka; (514), firmware određuje
The method of claim 1, wherein the determining whether the receiver has an empty buffer to be able to receive the data comprises determining that the receiver is delayed in being able to receive the data at a time the data is being sent. 
Postupak sukladno zahtjevu 1, pri čemu određivanje ima li primatelj prazan ublaživač radi prihvata podataka obuhvaća određivanje je li primatelj u zakašnjenju s primanjem podataka u vrijeme kada se podaci šalju.
A computer program product for facilitating communications in a communications environment, said computer program product comprising: a computer readable storage medium readable by a processing circuit and storing instructions for execution by the processing circuit for performing a method as claimed in claim 1 or claim 2. 
Proizvod računalni program u komunikacijskom okolišu, proizvod računalni program obuhvaća: medij za pohranu koji je moguće očitati računalom koji je moguće čitati krugom za obradu i upute za skladištenje za izvršenje putem kruga za obradu za provođenje metode sukladno zahtjevu 1 ili zahtjevu 2.
The computer program product of claim 3 when dependent on claim 2, wherein the pre-authorization operation block (QAOB) comprises a memory block to track the asynchronous data transfer. 
Proizvod računalni program sukladno zahtjevu 3 kada ovisi o zahtjevu 2, pri čemu predautorizacijski operacijski blok (QAOB) sadrži memorijski blok kako bi se pratilo asinkroni prijenos podataka.